首页> 外文OA文献 >Imunohistokemijski algoritmi subklasifikacije difuznog B-velikostaničnog limfoma Immunohistochemical algorithms for diffuse large B cell lymphoma subclassification
【2h】

Imunohistokemijski algoritmi subklasifikacije difuznog B-velikostaničnog limfoma Immunohistochemical algorithms for diffuse large B cell lymphoma subclassification

机译:弥漫性B细胞淋巴瘤亚分类的免疫组织化学算法弥漫性大B细胞淋巴瘤亚分类的免疫组化算法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Diffuse large B cell lymphoma, not otherwise specified (DLBCL-NOS) is a heterogenous group of aggressive non-Hodgkin lymphomas for which new molecular and immunohistochemical prognostic parameters are needed. This study included 107 patients with DLBCL-NOS stratified into GCB and non-GCB/ABC subgroup according to the immunohistochemical algorithms proposed by Hans et al. and Choi et al. with a purpose to analyse their prognostic value and correlation to other prognostic parameters. Patients in the non-GCB group according to the Hans' algorithm had significantly shorter event free survival, higher frequency of relapse and unfavorable outcome. No prognostic significance was observed after subclassification according to the Choi's algorithm. These results imply that in the observed patient group immunohistochemical subclassification according to the Hans' algorithm offers better prognostic information than Choi's algorithm.udThis study was also undertaken to test the prognostic significance of CD5 and CD43 markers, as well as c-MYC translocation in DLBCL. Also, the distribution of CD5 and CD43 expression in the GCB and non-GCB/ABC groups was analyzed according to both algorithms. There was no significant correlation between CD5 and CD43 expression and survival, response to therapy or outcome. Prognostic significance of c-MYC translocation could not be analyzed because the incidence of c-MYC translocation in this group of patients was lower than expected. udAlthough the correlation between CD5 and CD43 expression and non-GCB/ABC subgroup did not reach statistical significance, both markers were more frequently distributed in the non-GCB/ABC subgroup. Abberant expression of these markers in tumor cells, as well as correlation between CD43 expression and lack of BCL6 and GCET1 in tumor cells implicates a role these proteins might have in the oncogenesis of the more aggressive form of disease. The study gives a new insight into DLBCL pathogenesis and demonstrates the practical problems in the application of immunohistochemical algorithms in the routine clinical practice.ud
机译:弥漫性大B细胞淋巴瘤,未另作说明(DLBCL-NOS)是一组侵袭性非霍奇金淋巴瘤,需要新的分子和免疫组化预后参数。根据Hans等人提出的免疫组织化学算法,该研究纳入107例DLBCL-NOS分层为GCB和非GCB / ABC亚组的患者。和Choi等。目的是分析其预后价值以及与其他预后参数的相关性。根据Hans算法,非GCB组的患者无事件生存期明显缩短,复发频率较高,并且预后不良。根据Choi算法对子分类后,未观察到预后意义。这些结果表明,在所观察的患者组中,根据Hans算法进行的免疫组化亚分类比Choi算法能够提供更好的预后信息。 ud本研究还旨在检验CD5和CD43标记物以及c-MYC易位的预后意义。 DLBCL。而且,根据两种算法分析了GCB组和非GCB / ABC组中CD5和CD43表达的分布。 CD5和CD43表达与生存率,对治疗的反应或结果之间无显着相关性。无法分析c-MYC易位的预后意义,因为这组患者中c-MYC易位的发生率低于预期。虽然CD5和CD43表达与非GCB / ABC亚组之间的相关性未达到统计学显着性,但两种标志物在非GCB / ABC亚组中分布更为频繁。这些标志物在肿瘤细胞中的异常表达以及CD43表达与肿瘤细胞中BCL6和GCET1缺乏之间的相关性暗示这些蛋白质可能在更具侵略性的疾病的肿瘤发生中发挥作用。该研究为DLBCL的发病机理提供了新的见解,并证明了免疫组织化学算法在常规临床实践中的应用存在实际问题。

著录项

  • 作者

    Dotlić Snježana;

  • 作者单位
  • 年度 2012
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号